GammaCoeur™ addresses the need for a new cardiovascular disease (CVD) risk assay to complement traditional testing methods such as Total Fibrinogen, Cholesterol, Triglyceride and Glucose, for heart attack and stroke risk. Like all Gamma Therapeutic products, GammaCoeur is based on a natural clotting protein in blood called Gamma Prime Fibrinogen, shown in studies to have a strong and significant correlation with cardiovascular disease.  Despite current diagnostic tests to assess heart disease or stroke risk, millions die each year from fatal heart attacks—500,000 in the U.S. alone in 2009—many of which were preventable with more predictive testing methods. A simple non-invasive GammaCoeur blood test may give cardiologists more heart risk data and greater confidence in their prognosis.  Early studies indicate that if Gamma Prime and total Fibrinogen are elevated in the blood, in the upper 33rd percentile, it can indicate a 3X increased odds of heart attack, and if Gamma Prime Fibrinogen is in the upper 25th percentile, it can indicate a 7X increased odds of coronary artery disease. Cholesterol tests normally indicate a 2X risk. Millions of these tests are carried out annually and will increase as diagnostic testing becomes the focal point of preventative care.

In the U.S alone, $506 B is spent annually on heart disease, including physician visits, treatment, drugs, diagnostics, hospitalization and surgeries.  Approximately $1.36 B of this total represents spending on cardiac risk diagnostic testing. The value of the general IVD market, including cardiovascular-related diagnostics, is estimated to reach $50 billion by 2012—according to Decision Resources.

View GammaCoeur Articles

Copyright © 2010, Gamma Therapeutics, Inc. All rights reserved.